Apollomics Inc.
Business
Apollomics is a clinical-stage biopharmaceutical company focused on discovering and developing oncology therapies targeting difficult-to-treat cancers through targeted, immuno-oncology, and innovative approaches. The company's pipeline includes vebreltinib (a c-Met inhibitor), APL-102, and immuno-oncology candidates (APL-501, APL-502, APL-801) at various stages of clinical development. Apollomics operates globally with development teams in the San Francisco Bay Area and Hangzhou, China, and has partnerships with Avistone (China), CTTQ (China), Genor (China), RevMab, and LaunXP (Asia ex-China). The company pursues a capital-efficient model by seeking development and commercialization partners rather than building internal commercial infrastructure.
Summary from 20-F filed 2026-04-24
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-10.94M |
| Total assets | $6.71M |
| Total liabilities | — |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Apollomics Inc.'s CIK number?
Apollomics Inc.'s SEC CIK number is 0001944885 (1944885). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Apollomics Inc.'s SEC filings?
All of Apollomics Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.